Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 5-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past five years. As of today (2026-07-30), Ebos Group's 5-Year Sortino Ratio is 0.07.
Ebos Group (OTCPK:EBOSF) 5-Year Sortino Ratio Explanation
The 5-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past five year. It is calculated as the annualized result of the average five-year monthly excess returns divided by the standard deviation of negative returns in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.
Ebos Group 5-Year Sortino Ratio Related Terms
EBOSF vs MCK, COR, CAH: 5-Year Sortino Ratio Comparison
For the Medical Distribution subindustry, Ebos Group's 5-Year Sortino Ratio, along with its competitors' market caps and 5-Year Sortino Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group 5-Year Sortino Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's 5-Year Sortino Ratio distribution charts can be found below:
* The bar in red indicates where Ebos Group's 5-Year Sortino Ratio falls into.
The 5-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last five year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 5-Year Sortino Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past five year.
A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.
Ebos Group (EBOSF) has a 5-Year Sortino Ratio of 0.07 as of Jul. 30, 2026. 5-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past five years. View historical data for Ebos Group and its competitors.
Is Ebos Group's 5-Year Sortino Ratio too high?
Ebos Group's current 5-Year Sortino Ratio is 0.07. Overall, Ebos Group has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's 5-Year Sortino Ratio compare to MCK and COR?
Ebos Group's 5-Year Sortino Ratio of 0.07 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Sortino Ratio for a Medical Distribution company?
A good 5-Year Sortino Ratio depends on the Medical Distribution industry context. However, 5-Year Sortino Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Sortino Ratio mean?
A high 5-Year Sortino Ratio can signal that a stock is expensive relative to its fundamentals. 5-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past five years. View historical data for Ebos Group and its competitors. Ebos Group's current 5-Year Sortino Ratio is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSF) has a current 5-Year Sortino Ratio of 0.07. The stock's GF Value™ is $43.41, compared to a current price of $23.75 — trading 45.3% below its estimated fair value. The current 5-Year Sortino Ratio is 0.07. Ebos Group's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Sortino Ratio calculated?
5-Year Sortino Ratio is calculated from a company's financial statements. For Ebos Group (EBOSF), the current 5-Year Sortino Ratio is 0.07 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (EBOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of $23.75 is trading 45.3% below its estimated GF Value™ of $43.41.
Key valuation signals for EBOSF:
5-Year Sortino Ratio: 0.07
GF Value™: $43.41 vs. price of $23.75 (45.3% below fair value)
No single metric tells the full story. See the EBOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
85GF Score
Get the complete analysis for EBOSF
5-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBOSF has been successfully added to your 
